Fernandez-Martinez et al. reported that gene expression signatures related to intrinsic subtype and immune activation contribute to predicting pCR and survival outcomes using tumor gene expression profiles from Cancer and Leukemia Group B 40601, a dual HER2 blockade added to neoadjuvant chemotherapy in HER2-positive breast cancer [8]. This evidence concerns the gene ERBB2 and breast cancer.